US 11,786,577 B2
HIV treatment compositions and methods
Kayvan Niazi, Culver City, CA (US); Jeffrey Safrit, Culver City, CA (US); and John H. Lee, Culver City, CA (US)
Assigned to NantCell, Inc., Culver City, CA (US)
Filed by NantCell, Inc., Culver City, CA (US)
Filed on Sep. 15, 2021, as Appl. No. 17/475,783.
Application 17/475,783 is a continuation of application No. 16/443,560, filed on Jun. 17, 2019, granted, now 11,311,603.
Claims priority of provisional application 62/686,846, filed on Jun. 19, 2018.
Prior Publication US 2022/0016214 A1, Jan. 20, 2022
Int. Cl. A61K 35/17 (2015.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/10 (2006.01); A61K 38/20 (2006.01); A61K 31/167 (2006.01); A61K 31/4045 (2006.01); A61K 31/192 (2006.01); A61K 31/4406 (2006.01); A61K 31/215 (2006.01); C07K 14/735 (2006.01); A61K 31/506 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/215 (2013.01); A61K 31/4045 (2013.01); A61K 31/4406 (2013.01); A61K 31/506 (2013.01); A61K 35/17 (2013.01); A61K 39/12 (2013.01); C07K 14/70535 (2013.01); C07K 16/1063 (2013.01)] 20 Claims
 
1. A treatment kit for use in reducing a latent viral reservoir in an HIV infected individual, the kit comprising ALT-803 and a histone deacetylase (HDAC) inhibitor;
wherein the ALT-803 and the HDAC inhibitor are present in sufficient quantity to trigger, upon administration to the individual, expression of viral antigens in the HIV infected cell.